Cariprazine as a strategy for augmentation of treatment of major depressive disorder: from pharmacological aspects to clinical practice

Major depressive disorder remains the leading cause of disability worldwide, with up to 33% of patients failing to respond to antidepressant therapy. One promising strategy for the treatment of resistant depression is augmentation of antidepressant therapy with atypical antipsychotics. Cariprazine, a third-generation drug with a unique receptor profile, has demonstrated significant superiority over placebo in reducing symptoms of depression, anxiety, and anhedonia. The most optimal dose in most cases is 1.5 mg/day. Higher doses are associated with an increase in adverse drug reactions without enhancing the antidepressant effect. Cariprazine also reduces the frequency of hospitalizations and economic costs of treatment compared with other atypical antipsychotics in the treatment of major depressive disorder. Early administration of cariprazine as a first-line augmentation of antidepressant therapy is associated with better outcomes. The putative mechanism of antidepressant action is modulation of the dopamine and serotonin systems. Cariprazine is metabolized primarily by CYP3A4 to form active metabolites with a long half-life. Therefore, it is undesirable to combine the drug with strong and moderate CYP3A4 inhibitors and inducers. Cariprazine is not a p-glycoprotein substrate, which increases its efficacy and safety in patients — slow transporters. However, it exhibits properties of a weak p-glycoprotein inhibitor. In this regard, additional monitoring of adverse drug reactions may be required when using cariprazine with p-glycoprotein substrates and inhibitors. The most favorable pharmacokinetic interaction is observed in a combination of cariprazine and trazodone. There is currently insufficient information on the ratio of efficacy/tolerability indicators of cariprazine with various antidepressants, which necessitates further studies to clarify the optimal combinations and doses of drugs.

1. Bairamova SP, Pavlova OV, Shport SV, Gurina OI, Pavlov KA. The relationship of cytochrome P450 isoforms with the efficacy and safety of antipsychotic and antidepressant therapy. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(11):40-46. (In Russ.) doi:10.17116/jnevro202312311140

2. State Register of Medicines. Ministry of Health of the Russian Federation. Reagila. [grls.rosminzdrav.ru] 2025 [published April 9 2025, cited July 10 2025.] Available: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f6c9fa97-7922-4181-8c52-003cac3b2927

3. Dorozhenok IYu, Strukova AV. Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):36-42. (In Russ.) doi.org:10.17116/jnevro202412404136

4. Clinical guidelines: Depressive episode. Recurrent depressive disorder (2024). Ministry of Health of the Russian Federation. [cr.minzdrav.gov.ru] 2024. [published August 26 2024, cited July 10 2025] Available: https://cr.minzdrav.gov.ru/preview-cr/301_3

5. Mazo GE, Gorobets LN. Strategy of augmentation as a type of combined therapy in patients with depressive disorders (lithium and thyroid hormones). Sots Klin Psikhiatr. 2020;30(2):52-61. (In Russ.)

6. Mazo GE, Neznanov NG. Depressive Disorder. 3rd ed. GEOTAR-Media; 2025. (In Russ.) doi:10.33029/9704-9030-3-DED-2025-1-136

7. Mazo GE, Rukavishnikov GV, Kibitov AO. Therapeutic resistance in depression from the genetics and pharmacogenetics point of view. V M Bekhterev Rev Psychiatry Med Psychol. 2019;(4-1):43-47. (In Russ.) doi:10.31363/2313-7053-2019-4-1-43-47

8. Mosolov SN, Alfimov PV. The role of dopamine D3 receptors in the mechanism of action of modern antipsychotics. Sovrem Ter Psikh Rasstroistv. 2014;(1):2-9. (In Russ.)

9. Mosolov SN, Malin DI, Ryvkin PV, Sychev DA. Drug interactions of drugs used in psychiatric practice. Sovrem Ter Psikh Rasstroistv. 2019;(S1):2-33. (In Russ.) doi:10.21265/PSYPH.2019.50.40828

10. Nasyrova RF. The third-generation antipsychotic cariprazine as a promising drug for the treatment of depressive disorders. Sovrem Ter Psikh Rasstroistv. 2023;(2):21-29. (In Russ.) doi:10.21265/PSYPH.2023.86.41.003

11. Oleneva EV, Mosolov SN. The use of atypical antipsychotics to augment the effect of antidepressants in therapy-resistant episodes of recurrent depression. Sovrem Ter Psikh Rasstroistv. 2021;(4):2-13. (In Russ.) doi:10.21265/PSYPH.2021.26.96.001

12. Fomin EV, Baychorov IH, Shih EV, Sizova ZhM. Preclinical investigation of pharmaceuticals impact against cytochrome P450 activity and prognosis of substrate affinity as means for providing substrate therapy safety. Antibiot Khimioter. (In Russ.) 2013;58(7-8):34-39.

13. Agomelatine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB06594

14. Ali E, Latif F, Mashkoor Y, et al. Role of adjunctive cariprazine for treatment-resistant depression in patients with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Asian J Psychiatr. 2024;95:104005. doi:10.1016/j.ajp.2024.104005

15. Amitriptyline. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00321

16. Andrade C. Practical psychopharmacology: using a knowledge of pharmacokinetics to more rapidly stabilize patients at lower drug doses. J Clin Psychiatry. 2022;83(6):22f14722. doi:10.4088/JCP.22f14722

17. Bai B, Li Y, Chen X, et al. The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. BMC Psychiatry. 2025;25(1):338. doi:10.1186/s12888-025-06783-7

18. Barabassy A, Csehi R, Dombi ZB, et al. Transdiagnostic efficacy of cariprazine: a systematic review and meta-analysis of efficacy across ten symptom domains. Pharmaceuticals (Basel). 2025;18(7):995. doi:10.3390/ph18070995

19. Batinic B, Ristic I, Zugic M, Baldwin DS. Treatment of symptom clusters in schizophrenia, bipolar disorder and major depressive disorder with the dopamine D3/D2 preferring partial agonist cariprazine. Front Psychiatry. 2021;12:784370. doi:10.3389/fpsyt.2021.784370

20. Boyko IR, Shnayder NA, Grechkina VV, et al. Frequency of «Poor Transporter» phenotype among patients with mental disorders: Pilot study. Personal Psychiatry Neurol. 2024;4(3):37-44. doi:10.52667/2712-9179-2024-4-3-37-44

21. Bundgaard C, Eneberg E, Sánchez C. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo. Neuropharmacology. 2016;103:104-11. doi:10.1016/j.neuropharm.2015.12.009

22. Chen Z, Fan L, Wang H, et al. Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties. Nat Neurosci. 2022;25(1):39-49. doi:10.1038/s41593-021-00971-w

23. Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. CNS Spectr. 2017;22(6):484-494. doi:10.1017/S1092852916000894

24. Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI. Long-term effects of cariprazine exposure on dopamine receptor subtypes. CNS Spectr. 2014;19(3):268-277. doi:10.1017/S1092852913000680

25. Citalopram. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00215

26. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9(2):193-206. doi:10.1517/17425255.2013.759211

27. Citrome L, Reda I, Kerolous M. Adjunctive cariprazine for the treatment of major depressive disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2025;369:1238-1247. doi:10.1016/j.jad.2024.10.040

28. Clayton AH, Parikh M, Yee T, et al. Healthcare resource utilization with adjunctive cariprazine and other atypical antipsychotics in patients with major depressive disorder. Curr Med Res Opin. 2025;41(2):219-226. doi:10.1080/03007995.2025.2465617

29. Clomipramine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB01242

30. De Deurwaerdère P. Cariprazine: new dopamine biased agonist for neuropsychiatric disorders. Drugs Today (Barc). 2016;52(2):97-110. doi:10.1358/dot.2016.52.2.2461868

31. Duloxetine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00476

32. Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371-378. doi:10.4088/JCP.15m10070

33. Duric V, Banasr M, Franklin T, et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol. 2017;20(10):788-796. doi:10.1093/ijnp/pyx038

34. El Mansari M, Ebrahimzadeh M, Hamati R, et al. Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin receptor neurotransmission in the hippocampus. J Psychopharmacol. 2020;34(10):1143-1154. doi:10.1177/0269881120936891

35. Escitalopram. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB01175

36. Fava GA, Cosci F, Guidi J, Rafanelli C. The deceptive manifestations of treatment resistance in depression: a new look at the problem. Psychother Psychosom. 2020;89(5):265-273. doi:10.1159/000507227

37. Fava M, Masand PS, Maletic V, et al. Efficacy of adjunctive cariprazine on anxiety symptoms in patients with major depressive disorder: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2025;86(2):24m15506. doi:10.4088/JCP.24m15506

38. Fluoxetine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00472

39. Fluvoxamine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00176

40. Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317(15):1517. doi:10.1001/jama.2017.3826

41. Gill H, Chen-Li DCJ, Haikazian S, et al. Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis. CNS Spectr. 2024;29(4):233-242. doi:10.1017/S1092852924000178

42. Girgis RR, Slifstein M, D’Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl). 2016;233(19-20):3503-3512. doi:10.1007/s00213-016-4382-y

43. Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012;(213):167-210. doi:10.1007/978-3-642-25758-2_7

44. Hafizi S, Jones PB, Stahl SM, et al., editors. Cambridge Prescriber’s Guide in Psychiatry. Cambridge University Press; 2023. doi:10.1017/9781108986335

45. Health Canada. Approved Drug Products: VRAY-LAR (Cariprazine) Oral Capsules. [published April 22, 2022. cited July 12 2025] Available: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/vraylar-pm-eng-22apr2022.pdf

46. Hope J, Keks NA. Cariprazine: a new partial dopamine agonist with a familiar profile. Australas Psychiatry. 2022;30(3):382-385. doi:10.1177/10398562211064254

47. Huang M, He W, Kiss B, et al. The role of dopamine D3 receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens. J Pharmacol Exp Ther. 2019;371(2):517-525. doi:10.1124/jpet.119.259879

48. Huang W, Hu W, Cai L, et al. Acetate supplementation produces antidepressant-like effect via enhanced histone acetylation. J Affect Disord. 2021;281:51-60. doi:10.1016/j.jad.2020.11.121

49. Imipramine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00458

50. Kasyanov E, Yakovleva Y, Khobeysh M, Gerasimchuk E, Mazo G. Lifetime prevalence of recurrent and persistent depression: a scoping review of epidemiological studies. Clin Pract Epidemiol Ment Health. 2025;21:e17450179372815. doi:10.2174/0117450179372815250516102324

51. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328-340. doi:10.1124/jpet.109.160432

52. Ľupták M., Fišar Z., Hroudová J. Effect of Novel Antipsychotics on Energy Metabolism—In Vitro Study in Pig Brain Mitochondria. Mol Neurobiol. 2021;58(11):5548–5563. doi:10.1007/s12035-021-02498-4

53. Martins-Correia J, Fernandes LA, Kenny R, et al. Cariprazine in the acute treatment of unipolar and bipolar depression: a systematic review and meta-analysis. J Affect Disord. 2024;362:297-307. doi:10.1016/j.jad.2024.06.099

54. Masand PS, Clayton AH, Parikh M, et al. Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder. J Med Econ. 2025;28(1):235-244. doi:10.1080/13696998.2025.2457872

55. McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394-412. doi:10.1002/wps.21120

56. McIntyre RS, Maletic V, Masand P, et al. The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. J Affect Disord. 2025;385:119366. doi:10.1016/j.jad.2025.05.026

57. McIntyre RS, Parikh M, Ta J, et al. Real-world effectiveness of cariprazine in major depressive disorder and bipolar I disorder in the United States. J Med Econ. 2025;28(1):885-898. doi:10.1080/13696998.2025.2513766

58. Meltzer HY, Gadaleta E. Contrasting typical and atypical antipsychotic drugs. Focus (Am Psychiatr Publ). 2021;19(1):3-13. doi:10.1176/appi.focus.20200051

59. Mianserin. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB06148

60. Mirtazapine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00370

61. Nasyrova RF, Shnayder NA, Osipova SM, et al. Genetic predictors of antipsychotic efflux impairment via blood-brain barrier: role of transport proteins. Genes. 2023;14(5):1085. doi:10.3390/genes14051085

62. Nuñez NA, Joseph B, Pahwa M, et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. J Affect Disord. 2022;302:385-400. doi:10.1016/j.jad.2021.12.134

63. O’Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol. 2012;165(2):289-312. doi:10.1111/j.1476-5381.2011.01557.x

64. Orsolini L, De Berardis D, Volpe U. Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opin Drug Saf. 2020;19(8):981-998. doi:10.1080/14740338.2020.1795126

65. Otmakhov AP, Proydina DS, Kibirova AY, Kidyaeva AV, Nasyrova RF. The role of pharmacogenetic testing in optimizing antipsychotic therapy. Personal Psychiatry Neurol. 2024;4(4):34-42. doi:10.52667/2712-9179-2024-4-4-34-42

66. Paroxetine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00715

67. Pejušković B, Munjiza Jovanović A, Pešić D. Exploring cariprazine as a treatment option for varied depression symptom clusters. Front Psychiatry. 2024;15:1442699. doi:10.3389/fpsyt.2024.1442699

68. Sachs GS, Yeung PP, Rekeda L, et al. Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study. Am J Psychiatry. 2023;180(3):241-251. doi:10.1176/appi.ajp.20220504

69. Saiz-Rodríguez M, Ochoa D, Belmonte C, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol. 2019;33(4):522-531. doi:10.1177/0269881119827959

70. Sertraline. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB01104

71. Shnayder NA, Kidyaeva AV, Vaiman EE, et al. Role of pharmacokinetics and pharmacogenetics of antidepressant-induced prolongation of the QT interval and torsade de pointes in patients with mental disorders. Personal Psychiatry Neurol. 2023;3(2):72-119. doi:10.52667/2712-9179-2023-3-2-72-119

72. Spieler D, Namendorf C, Namendorf T, Uhr M. ABCB1ab p-glycoprotein is involved in the uptake of the novel antidepressant vortioxetine into the brain of mice. J Psychiatr Res. 2019;109:48-51. doi:10.1016/j.jpsychires.2018.11.009

73. Tarzian M., Ndrio M., Kaja S. et al. Cariprazine for treating schizophrenia, mania, bipolar depression, and unipolar depression: A review of its efficacy. Cureus. 2023;15:5. doi:10.7759/cureus.39309

74. Terao I, Kodama W. Comparative efficacy of dopamine partial agonists by doses for treatment-resistant depression: a systematic review and dose-response model-based network meta-analysis. J Clin Psychopharmacol. 2024;44(4):413-417. doi:10.1097/JCP.0000000000001862

75. Thase ME, Yeung PP, Rekeda L, Liu M, Varughese S. Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials. Int Clin Psychopharmacol. 2025;40(1):27-36. doi:10.1097/YIC.0000000000000528

76. Trazodone. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00656

77. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57:203-209. doi:10.1016/j.neuron.2007.11.017

78. Venlafaxine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB00285

79. Vortioxetine. DrugBank. [go.drugbank.com] 2025. [cited July 15 2025.] Available: https://go.drugbank.com/drugs/DB09068

80. Xie M, Qiu Y, Wang M, et al. Adjunctive cariprazine as a novel effective strategy for treating major depressive disorder: a systematic review and meta-analysis. J Psychiatr Res. 2024;172:71-80. doi:10.1016/j.jpsychires.2024.02.018